Editors' Desk

  1. The Rise Of NAMs 7/31/2025

    New Approach Methods (NAMs) are rapidly being accepted as replacements for preclinical animal tests long considered to be the gold standard. NAMs include systems of organoids, organs-on-chips, AI-based prediction models, and non-mammalian species.

  2. The 3 Big Barriers To AMT Implementation 7/18/2025

    Advanced manufacturing technologies (AMTs) can not only lower costs but also improve the quality and consistency of both API and final dosage manufacturing in pharmaceuticals, so why are they not more widely implemented?

  3. Can AMTs Make U.S. Pharmaceuticals Faster, Better, Stronger? 7/11/2025

    As the pharmaceutical industry prepares for impending tariffs and invests in domestic manufacturing, advanced manufacturing technologies present a viable opportunity to modernize systems for improved efficiency, consistent quality and potentially lower costs.

  4. How Modular Facility Design Can Accelerate GMP Facility Construction 5/20/2025

    Autolus Therapeutics' COO talks about the accelerated construction of the company's cell therapy manufacturing facility, The Nucleus.

  5. A Facilities Expert Answers Audience Questions On Construction And Validation 5/5/2025

    Bioprocessing facility expert Herman Bozenhardt responds to some unanswered audience questions from a Pharmaceutical Online Live event on facility design and validation.

  6. Experts' Advice On Facility Design And Construction 4/24/2025

    This is a review of the Pharmaceutical Online Live event “Facility Design And Validation Considerations For Drug Manufacturers," which featured industry experts Erich Bozenhardt and Herman Bozenhardt, as well as process architect Fred Grossfeld.

  7. Areas For Advancement In Peptide Manufacturing 2/27/2025

    Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.

  8. For Gilead, Sustainability Is More Than A PR Effort 2/14/2025

    Gilead's chief sustainability officer and SVP of operations, Joydeep Ganguly, explains the company's cultural focus on sustainability and how it influences everything from R&D to manufacturing. 

  9. Antibodies 2025: Venerable & Naked Or Complex & Multi-Specific? 12/19/2024

    Antibodies are the biotherapeutic bulwark, the steadfast stalwart in not just oncology, but infectious and chronic inflammatory diseases as well. We consulted with a variety of antibody developers for insight into the challenges and opportunities antibody modalities face in the coming year and beyond.

  10. The ADC Market Is Ripening For Disruption 8/21/2024

    Where there is therapeutic demand, the industry will build capacity. But with ADCs, cytotoxic payloads and a fragmented contract manufacturing landscape make the path to clinical and commercial supply dauntingly complicated. Here's how the ADC manufacturing market is shaping up, and how it might ultimately shake out.